Abstract 1708P
Background
Since China implemented the regulations on adjusting the approval process of imported drugs in 2017, the integration of China into the global development of novel anticancer drugs has accelerated. The changing registration pathways for these products inspire us to present this data analysis.
Methods
Based on the review reports of approved global anticancer drugs from the database of the Center of Drug Evaluation of China, the cancer type, scope and timeline of pivotal supporting trials for each indication were extracted by the end of 2022. The distribution of registration pathways was explored using the number of indications as the key indicator.
Results
A total of 83 approved indications were retrieved. Participating in synchronous global studies (39, 47.0%) was the most common registration pathway, which was divided into dose expansion/phase II (4, 4.8%) and confirmatory studies (35, 42.2%). Launching China-dominant studies was another main pathway (35, 42.2%), including bridging (26, 31.3%) and confirmatory studies (10, 12.0%). Clinical studies in China were exempted in 15 (18.1%) indications. Multiple pathways were used to support 7 (8.4%) indications. The number of indications supported by China-dominant studies decreased from 19 (2017-2019) to 15 (2020-2022), while that of synchronous global studies increased from 15 (2017-2019) to 23 (2020-2022). Among the 9 indications for esophageal, gastric and hepatocellular cancer, eight (88.9%) were approved by global studies. The median days between China and the first global approval was 371 in indications supported by global studies, compared with 1326 in that supported by China-dominant studies.
Table: 1708P
No. of indications | ||||||||
Year | Dose-expansion/phase II | Global confirmatory studies | Synchronous global studies | Bridging studies | China-dominant confirmatory studies | China-dominant studies | Exemption of clinical studies in China | Total |
2015 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 |
2017 | 1 | 2 | 3 | 3 | 2 | 5 | 1 | 7 |
2018 | 0 | 5 | 5 | 5 | 2 | 6 | 0 | 10 |
2019 | 2 | 5 | 7 | 5 | 3 | 8 | 4 | 18 |
2020 | 0 | 9 | 9 | 4 | 1 | 5 | 5 | 19 |
2021 | 0 | 8 | 8 | 4 | 2 | 6 | 4 | 17 |
2022 | 1 | 5 | 6 | 4 | 0 | 4 | 1 | 11 |
Total (%) | 4(4.8%) | 35(42.2%) | 39(47.0%) | 26(31.3%) | 10(12.0%) | 35(42.2%) | 15(18.1%) | 83(100.0%) |
Median days between China and global approval | 1399 | 365 | 371 | 1230 | 2082 | 1326 | 2064 | 1045 |
Conclusions
Participating in synchronous global studies is the most common and time-saving registration pathway in China for globally developed novel anticancer drugs in recent years, especially for Chinese high-prevalent cancers. Efforts should be made to help China join more global early-phase studies in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1737P - Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Presenter: Maria Eugenia Olmedo Garcia
Session: Poster session 23
1738P - Impact of digital platforms on exposure to tobacco and new smoking devices: A survey approach
Presenter: Diego de Haro
Session: Poster session 23
1739P - Lung cancer mortality patterns of tobacco users in the United States: A 21-year analysis (1999-2020)
Presenter: Seif Bugazia
Session: Poster session 23
1740P - Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Presenter: Moisés González-Escamilla
Session: Poster session 23
1741P - Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Presenter: Valentin Vidal
Session: Poster session 23
1742P - Gender differences in incidence trends of early-onset GI cancer: The European perspective
Presenter: Irit Ben-Aharon
Session: Poster session 23
1743P - Bridging the gender gap in oncology: GEORGiNA'S quest for equality in academic research
Presenter: Khalid El Bairi
Session: Poster session 23
1744P - Socioeconomic inequalities in the diagnosis and treatment of colon cancer: A population-based English cancer registry study
Presenter: Benjamin Pickwell-Smith
Session: Poster session 23
1745P - Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Presenter: Reshma Ayiraveetil
Session: Poster session 23
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23